A LinkedIn post from bwell Connected Health highlights survey data suggesting rapid growth in U.S. consumer use of AI chatbots for health information, rising from 16% to 32% in a year. The post emphasizes that patients are increasingly turning to AI for symptom checks and medication questions, framing this as a response to perceived gaps in traditional care access and guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post quotes founder and CEO Kristen Valdes as arguing that AI tools, while imperfect, may represent an incremental improvement if developed and governed responsibly. This perspective positions bwell Connected Health as focused on the “moment between AI query and clinical action,” which the company appears to view as a critical safety and quality inflection point for health systems.
From an investor standpoint, the post suggests bwell is aligning its strategy with accelerating consumer adoption of AI in healthcare and the need for infrastructure to manage AI-informed patient decisions. If bwell can offer platforms that help providers monitor, guide, and integrate these AI-driven interactions, it could strengthen its value proposition with payers and health systems and capture growing demand in digital health orchestration.
The emphasis on responsible use and quality safeguards may also indicate an attempt to differentiate in a crowded healthtech landscape where regulatory and liability concerns are increasing. Successful execution in this area could improve the company’s competitive position and potentially support long-term revenue opportunities tied to AI-enabled care navigation and patient engagement solutions.